Safety and efficacy of ZOLSOMA tablets in patients with insomnia

Sagar Karia; Manushree Gupta; Manjiri Dixit; Chytanya Deepak; Nilesh  Shah; Pankaj Verma; Vidyadhar G. Watve; K. Chandra Shekhar; Sindhu Amme; Harsh Chaturvedi

doi:10.18203/2320-6012.ijrms20261342

Authors

Sagar Karia Department of Psychiatry, LTM Medical College and General Hospital, Sion, Mumbai, Maharashtra, India
Manushree Gupta Department of Psychiatry, VMMC and Safdarjung Hospital, New Delhi, India
Manjiri Dixit Department of Psychiatry, Poona Hospital, Pune, Maharashtra, India
Chytanya Deepak Department of Psychiatry, Asha Hospital and Research Centre, Banjara Hill, Hyderabad, India
Nilesh Shah Department of Psychiatry, LTM Medical College and General Hospital, Sion, Mumbai, Maharashtra, India
Pankaj Verma Department of Psychiatry, VMMC and Safdarjung Hospital, New Delhi, India
Vidyadhar G. Watve Department of Psychiatry, VMMC and Safdarjung Hospital, New Delhi, India
K. Chandra Shekhar Department of Psychiatry, Asha Hospital and Research Centre, Banjara Hill, Hyderabad, India
Sindhu Amme Department of Psychiatry, Asha Hospital and Research Centre, Banjara Hill, Hyderabad, India
Harsh Chaturvedi Department of Psychiatry, Asha Hospital and Research Centre, Banjara Hill, Hyderabad, India

DOI:

https://doi.org/10.18203/2320-6012.ijrms20261342

Keywords:

Insomnia, Zolsoma, Zolpidem, Melatonin, Sleep disorders

Abstract

Background: Insomnia is difficulty falling asleep or staying asleep, even when a person has the chance to do so. Pharmacological management often relies on hypnotics such as zolpidem; however, high doses are linked to adverse effects. Combining zolpidem with melatonin, a circadian regulator with mild hypnotic activity, may enhance sleep quality while minimizing side effects. Aim of the study was to evaluate the safety and efficacy of a fixed-dose combination (FDC) of zolpidem and melatonin (ZOLSOMA-5) in patients with insomnia.

Methods: This open-label, single-arm, multicentre, prospective study was conducted between October 2021 and October 2024. Participants received ZOLSOMA-5 for 30 days. Efficacy was assessed using the Pittsburgh Sleep Quality Index (PSQI), and Insomnia Severity Index (ISI). Safety was evaluated using Epworth Sleepiness Scale (ESS) and based on adverse effects.

Results: Of 312 enrolled patients, 300 completed the study. Mean PSQI scores in intention-to-treat (ITT) set significantly decreased from 15.19±2.75 at baseline to 5.73±5.58 on day 30 (p<0.001). ISI scores reduced from 20.57±5.00 at baseline to 7.18±5.45 on day 30, respectively (p<0.001). ESS scores improved from 6.99±6.68 at baseline to 4.48±4.70 on day 30 (p<0.001). A total of 45 patients (14.4%) reported 60 adverse events (AEs), most commonly dizziness and nausea, the majority were mild and transient.

Conclusions: The FDC of ZOLSOMA-5 demonstrated significant improvement in sleep quality, reducing insomnia severity, and alleviating daytime sleepiness, with a favourable safety profile. The combination appears to be a safe and effective short-term therapeutic option for insomnia, including in patients with psychiatric comorbidities.

References

Bhaskar S, Hemavathy D, Prasad S. Prevalence of chronic insomnia in adult patients and its correlation with medical comorbidities. J Family Med Prim Care. 2016;5(4):780-4.

Ohayon MM. Epidemiology of insomnia: What we know and what we still need to learn. Sleep Med Rev. 2002;6:97-111.

Yang M, Morin CM, Schaefer K, Wallenstein GV. Interpreting score differences in the Insomnia Severity Index: using health-related outcomes to define the minimally important difference. Curr Med Res Opin. 2009;25(10):2487-94.

Mini JL, Weigand SW, Zhangh J. Self-Reported Efficacy and Tolerability of Ramelteon 8 mg in Older Adults Experiencing Severe Sleep-Onset Difficulty. Am J Geriatr Pharmacother. 2007;5(3):177-84.

Punja S, Nikles JC, Senior H, et al. Melatonin in Youth: N-of-1 trials in a stimulant-treated ADHD Population (MYNAP): study protocol for a randomized controlled trial. Trials. 2016; 17: 375.

Slominski RM, Reiter RJ, Ostrum RS, Rennolds SO, Andrzej TS. Melatonin membrane receptors in peripheral tissues: Distribution and functions. Mol Cell Endocrinol. 2012;351(2):152-66.

KD Tripathi, Essentials of Medical pharmacology, 7th edition, New Delhi: Jaypee Brothers Medical Publishers (P) Ltd; 2013;409.

Drug Bank: Melatonin. Available at: https://www.drugbank.ca/drugs/DB01065. Accessed on 25 January 2026.

Ambien. Highlights of Precribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/019908s027lbl.pdf. Accessed on 25 January 2026.

Gautam CS, Saha L. Fixed dose drug combinations (FDCs): rational or irrational: a view point. Br J Clin Pharmacol. 2008; 65(5):795-6.

Cheung J, Ruoff C.M, Mignot E. Chapter 8 - Central Nervous System Hypersomnias. Sleep and Neurologic Disease. Academic Press. 2017;141-66.

Zhong QY, Gelaye B, Sánchez SE, et al. Psychometric Properties of the Pittsburgh Sleep Quality Index (PSQI) in a Cohort of Peruvian Pregnant Women. J Clin Sleep Med. 2015;11(8):869-77.

Daniel F, Bryony S, Felicity W, Allison GH, Paul JH. Sleep disturbance and psychiatric disorders. Lancet Psychiat. 2020;7(7):628-37.

Sreedhar D, Subramanian G, Udupa N. Combination drugs: are they rational? Curr Sci. 2006;91:406.

Ohshima H, Kotorii N, Takii M, Hiroshi H, Mitsunari H, Hiroo K, et al. Polysomnographic Sleep Disturbances Due to High-Dose Zolpidem Use: A Case Report. J Clin Sleep Med. 2018;14(11):1949-52.

O'Donnell VM, Balkin TJ, Andrade JR, Simon L, Kamimori G, Redmond D, et al. Effects of triazolam on sleep and performance in a model of transient insomnia. Hum Perform. 1988;1:145-60.

Balkin TJ, O'Donnell VM, Wesensten N, McCann U, Belenky G. Comparison of the daytime sleep and performance effects of zolpidem vs. triazolam. Psychopharmacol (Berl). 1992;107:83-8.

Dollins AB, Zhdanova IV, Wurtman RJ, Lynch HJ, Deng MJ. Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance. Proc Natl Acad Sci U S A. 1994;91(5):1824-8.

Hughes RJ, Badia P. Sleep-promoting and hypothermic effects of daytime melatonin administration in humans. Sleep. 1997;20:124-31.

Reid K, Van Den Heuvel C, Dawson D. Day-time melatonin administration: Effects on core temperature and sleep onset latency. J Sleep Res. 1996;5:150-4.

Mishima K, Satoh K, Shimizu T, Hishikawa Y. Hypnotic and hypothermic action of daytime-administered melatonin. Psychopharmacology (Berl). 1997;133:168-71.

Rogers NL, Phan O, Kennaway DJ, Dawson D. Effect of daytime oral melatonin administration on neurobehavioral performance in humans. J Pineal Res. 1998;25:47-53.

Graw P, Werth E, Krauchi K, Gutzwiller F, Cajochen C, WirzJustice A. Early morning melatonin administration impairs psychomotor vigilance. Behav Brain Res. 2001;121:167-72.

Dollins AB, Lynch HJ, Wurtman RJ, Deng MH, Kischka KU, Gleason RE, et al. Effect of pharmacological daytime doses of melatonin on human mood and performance. Psychopharmacology (Berl). 1993;112(4):490-6.

Shahrokhi M, Ghaeli P, Arya P, Alia S, Afsaneh N, Mehdi S, et al. Comparing the Effects of Melatonin and Zolpidem on Sleep Quality, Depression, and Anxiety in Patients with Colorectal Cancer Undergoing Chemotherapy. Basic Clin Neurosci. 2021;12(1):105-14.

Buysse DJ, Ancoli-Israel S, Edinger JD, Kenneth LL, Charles MM, et al. Recommendations for a standard research assessment of insomnia. Sleep. 2006;29(9):1155-73.

Morin CM, Belleville G, Bélanger L, Hans I. The insomnia severity index: psychometric indicators to detect insomnia cases and evaluate treatment response. Sleep. 2011;34(5):601-8.

Motlaq TM, Rahimi B, Amini S. Effect of melatonin on insomnia and daytime sleepiness, in patients with obstructive sleep apnea and insomnia (COMISA): a randomized double-blinded placebo-controlled trial. J Pharm Health Care Sci. 2024;10:25.

Mehrpooya M, Ghasemian Z, Amini K, Kimia B, Maryam Z, Amir K, et al. Add-on therapy with melatonin in the acute bipolar mania treatment: results of a randomized, placebo-controlled trial. Nat Prod J. 2025;15(3):11.

Lippincott Williams and Wilkins. Sedatives and hypnotics, non-barbiturate. Zolpidem tartrate. In: Kastrup EK, editor, Drug facts and comparisons, 2017 edition. USA; Wolters Kluwer. 2017;2241-6.

Besag FMC, Vasey MJ, Lao KS, Ian CKW. Adverse Events Associated with Melatonin for the Treatment of Primary or Secondary Sleep Disorders: A Systematic Review. CNS Drugs. 2019;33(12):1167-86.

Jain S, Bhargava M, Gautam S. Weight gain with olanzapine: Drug, gender or age? Indian J Psychiatry. 2006;48(1):39-42.

Alonso-Juarez M, Torres-Russotto D, Crespo-Morfin P, José Fidel BC. The clinical features and functional impact of valproate-induced tremor. Parkinsonism Relat Disord. 2017;44:147-50.

Jaitpal V, Gawande S. Olanzapine-Induced Parkinsonism and Akathisia: A Case Report. Cureus. 2022;14(1):e21354.

Liebowitz MR, Tourian KA. Efficacy, safety, and tolerability of Desvenlafaxine 50 mg/d for the treatment of major depressive disorder: a systematic review of clinical trials. Prim Care Companion J Clin Psychiat. 2010;12(3):PCC.09r00845.

Pattanayak RD, Rajhans P, Shakya P, Namita G, Khandelwal SK. Lithium-induced polyuria and amiloride: Key issues and considerations. Indian J Psychiat. 2017;59(3):391-2.

Khurshid KA. Comorbid Insomnia and Psychiatric Disorders: An Update. Innov Clin Neurosci. 2018;15(3-4):28-32.